• Acadia Pharmaceuticals Inc., of San Diego, provided an update on the timing of its Phase II adjunctive therapy trial with ACP-103 in patients with schizophrenia, saying enrollment is ahead of schedule, which should enable the company to report top-line results for the complete 400-patient clinical trial during the first quarter of 2007, ahead of earlier expectations. The company no longer plans an interim analysis based on the first 200 patients, which had been planned to be conducted by the end of 2006. Acadia's stock (NASDAQ:ACAD) closed Monday at $8.20, up 32 cents.

• Adventrx Pharmaceuticals Inc., of San Diego, completed patient enrollment in a 300-patient Phase IIb trial designed to compare the safety and efficacy of 5-fluorouracil (5-FU) plus Adventrx's CoFactor to 5-FU plus leucovorin in first-line treatment of metastatic colorectal cancer. The trial began in the second quarter of 2005 and is expected to yield data in the second half of next year.

• Avera Pharmaceuticals Inc., of San Diego, completed enrollment in its ongoing Phase II study of the neurokinin-1 (NK-1) antagonist AV608 in subjects with social anxiety disorder. The 12-week study is taking place in the U.S., investigating the safety and efficacy of AV608, and has enrolled 182 subjects. Preliminary results are expected in early 2007.

• Biothera, of Eagan, Minn., completed its second Phase I trial of Imprime PGG, its lead compound for activating the body's own immune system to fight multiple types of cancer. The randomized, double-blinded, placebo-controlled study in healthy volunteers indicated that the product is safe and well tolerated over a wide dose range.

• Boston Life Sciences Inc., of Hopkinton, Mass., said results from the POET-1 (Parkinson's or Essential Tremor) demonstrated that scans with the Altropane molecular imaging agent showed statistically significant superiority over the diagnosis of PCPs on measures of both specificity and sensitivity, the study's primary endpoint. Specific numbers weren't disclosed, but the company said it is working with advisers and the FDA to determine the most direct route to approval and to finalize plans for POET-2 and the remaining clinical development of the product, which it expects to partner.

No Comments